Implementing simple interventions could significantly decrease screening mammography recall rates.
Simple interventions may reduce recall rates for women undergoing full-field digital mammography (FFDM) and digital breast tomosynthesis (DBT), according to a study published in Academic Radiology.
Researchers from Johns Hopkins University School of Medicine in Baltimore, MD, and Columbia University in New York City, wanted to determine the impact of interventions designed to reduce screening mammography recall rates on screening performance metrics.
The researchers assessed the baseline performance for FFDM and DBT for a 3-year period before intervention, and sought to increase awareness of recalls from screening mammography. The first intervention included breast imagers discussing their perceptions regarding screening recalls and were required to review their own recalled cases, including outcomes of diagnostic evaluation and biopsy. The second intervention implemented consensus double reading of all recalls, requiring two radiologists to agree if recall was necessary. Recall rates, cancer detection rates, and positive predictive value 1 (PPV1) were compared before and after each intervention.
The results showed a significant change in recall rates after the intervention:
Cancer detection rate did not significantly change with the implementation of these interventions. An average of 2.3 minutes was spent consulting for each recall.
The researchers concluded that their interventions improved performance and could be implemented in other breast imaging settings.
FDA Clears Updated AI Platform for Digital Breast Tomosynthesis
November 12th 2024Employing advanced deep learning convolutional neural networks, ProFound Detection Version 4.0 reportedly offers a 50 percent improvement in detecting cancer in dense breasts in comparison to the previous version of the software.
Is the Kaiser Score More Effective than BI-RADS for Assessing Contrast-Enhanced Mammography and MRI?
October 14th 2024For women with breast-enhanced masses, Kaiser scoring (KS) demonstrated a 20 percent higher AUC than BI-RADS classification for contrast-enhanced mammography (CEM) and was comparable to KS for breast MRI.
FDA Clears New Features in AI-Powered Mammography Software Suite
October 11th 2024Therapixel’s MammoScreen suite has received 510(k) FDA clearances for a breast density assessment feature and updated software that includes automated pre-reporting, which reportedly expedites reporting of mammography findings.